SCRN2 and neoplasm: This study defines SCRN2 as a novel tumor suppressor in TNBC to suppress cancer progression and enhance PARP inhibitor sensitivity through stabilizing KMT2C and reveals SCRN2 as a potential biomarker and therapeutic target for TNBC.